Capmatinib CAS 1029712-80-8

Khoom Qhia:

Khoom npe: capmatinib CAS TSIS: 1029712-80-8

Txhais:

INC280;

2-fluoro-N-methyl-4- [7- (quinolin-6-ylmethyl) -imidazo [1,2-b] [1,2,4] triazin-2-yl] benzamide;

Tshuaj& Cov Khoom Uas Lub Cev:

Zog: Cov hmoov daj ua kom zoo nkauj

Ntsuas: ≥99.0%

Dej Solubility: Insoluble

Soluble: Soluble hauv DMSO, tsis yog hauv dej

Qhov ntsuas ntawm kwv yees: 1.717

Capmatinib, tseem hu ua INCB28060 thiab INC280, yog qhov ncauj txwv tsis pub muaj lub cev tiv thaiv kab mob tiv thaiv proto-oncogene c-Met (hepatocyte kev loj hlob tau receptor [HGFR]) nrog cov kev ua haujlwm antineoplastic. Nws xaiv txoj hlua khi rau c-Met, yog li inhibiting c-Met phosphorylation thiab cuam tshuam c-Met teeb liab kis kab mob. Qhov no tej zaum yuav ua rau muaj kev tuag ntawm tes nyob rau hauv cov qog hlwb overexpressing c-Met protein los yog hais tawm ua ke c-Met protein. c-Met, ib qho receptor tyrosine kinase ua haujlwm ntau lossis hloov pauv hauv ntau hom qog nqaij hlav, ua lub luag haujlwm tseem ceeb hauv qog cell loj hlob, muaj sia nyob, ntxeem tau, metastasis, thiab mob qog angiogenesis. Nws tau tso cai rau Breakthrough Therapy Designation los ntawm FDA yog thawj txoj kab kev kho mob rau cov neeg mob uas muaj metastatic MET exon14 hla kev-tsis hloov cov hlwb tsis mob ntsws hauv hlwb (NSCLC).

Yog tias koj txaus siab rau peb cov khoom lossis muaj lus nug, thov koj xav tiv tauj peb!

Cov khoom lag luam hauv qab patent yog muab rau R& D lub hom phiaj nkaus xwb. Txawm li cas los xij, lub luag haujlwm kawg tau txiav txim siab nrog cov neeg yuav khoom.

Cim npe nrov: capmatinib cas 1029712-80-8, tuam ntxhab, lwm tus neeg, Hoobkas, yuav, hauv Tshuag

• Tug: Mobocertinib CAS 1847461-43-1
• Tom ntej: Savolitinib CAS 1313725-88-0